Literature DB >> 11323394

Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development.

J Ohno1, Y Horio, Y Sekido, Y Hasegawa, M Takahashi, J Nishizawa , H Saito, F Ishikawa, K Shimokata.   

Abstract

The mouse telomerase holoenzyme, which synthesizes telomeric DNA de novo, is a ribonucleoprotein complex that includes the mouse telomerase RNA component (mTERC), mouse telomerase-associated protein (mTEP1) and mouse telomerase reverse transcriptase (mTERT). To determine the role of telomerase in urethane-induced lung tumorigenesis in A/J mice we examined telomerase activity and the expression of each telomerase subunit in 20 tumor samples, harvested at 16, 28, 40 and 50 weeks after urethane treatment. The telomeric repeat amplification protocol assay showed that statistically significant telomerase activation occurred both early and late in tumorigenesis. Semi-quantitative reverse transcription-polymerase chain reaction analysis revealed that mRNA expression levels of mTEP1 and mTERT were up-regulated during tumor progression, while mTERC expression was not significantly different between tumors and normal lung. We further examined mTEP1 protein expression in normal lung tissue and lung tumors; western blot analysis showed preferential expression of mTEP1 protein in lung tumors compared with normal lung and immunohistochemistry revealed that a majority of the adenoma cells were positively stained in the nucleus, whereas only a few of the adjacent normal alveolar cells were immunoreactive. In addition, we investigated DNAs of the 20 tumor samples by single strand conformation polymorphism and sequencing analyses to examine whether alterations of the p53 gene in exons 5-8 were associated with telomerase activity. Although we found one nonsense, two missense, two silent and one simultaneous double mutation at different codons in six late stage tumors, there was no apparent correlation between telomerase activity and p53 mutations. Collectively, these results suggest that mTEP1 as well as mTERT may be involved in the regulation of telomerase activity and that telomerase activation may contribute to lung tumorigenesis in A/J mice independently of p53 gene alterations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323394     DOI: 10.1093/carcin/22.5.751

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  Complex regulation of telomerase activity: implications for cancer therapy.

Authors:  K S Elenitoba-Johnson
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

2.  Cl- channels in basolateral TAL membranes. XIX. Cytosolic Cl- regulates mmCIC-Ka and mcCIC-Ka channels.

Authors:  C J Winters; M V Mikhailova; T E Andreoli
Journal:  J Membr Biol       Date:  2003-09-15       Impact factor: 1.843

3.  Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells.

Authors:  Masahiro Takakura; Satoru Kyo; Masaki Inoue; Woodring E Wright; Jerry W Shay
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 4.  Overview of the molecular carcinogenesis of mouse lung tumor models of human lung cancer.

Authors:  Nobuko Wakamatsu; Theodora R Devereux; Hue-Hua L Hong; Robert C Sills
Journal:  Toxicol Pathol       Date:  2007-01       Impact factor: 1.902

5.  Inhibitory effect of all-trans retinoic acid on human hepatocellular carcinoma cell proliferation.

Authors:  Yun-Feng Piao; Yang Shi; Pu-Jun Gao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

6.  Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models.

Authors:  Jirí Svec; Peter Ergang; Václav Mandys; Milan Kment; Jirí Pácha
Journal:  Int J Exp Pathol       Date:  2010-02       Impact factor: 1.925

7.  Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway.

Authors:  David Blanco; Silvestre Vicent; Mario F Fraga; Ignacio Fernandez-Garcia; Javier Freire; Amaia Lujambio; Manel Esteller; Carlos Ortiz-de-Solorzano; Ruben Pio; Fernando Lecanda; Luis M Montuenga
Journal:  Neoplasia       Date:  2007-10       Impact factor: 5.715

Review 8.  Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.

Authors:  Amelia Kellar; Cay Egan; Don Morris
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.